Back to top
more

Kamada (KMDA)

(Delayed Data from NSDQ)

$5.78 USD

5.78
34,571

-0.05 (-0.86%)

Updated Jul 19, 2024 04:00 PM ET

After-Market: $5.88 +0.10 (1.73%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

New Strong Sell Stocks for August 25th

BEEM, CHRS, KMDA, STIM and PHUN have been added to the Zacks Rank #5 (Strong Sell) List on August 25, 2021

Kamada (KMDA) Q2 Earnings and Revenues Miss Estimates

Kamada (KMDA) delivered earnings and revenue surprises of -60.00% and -5.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Kamada (KMDA) to Report a Decline in Earnings: What to Look Out for

Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead (GILD) Inks Deal to Develop Allogeneic Cell Therapies

Gilead's (GILD) wholly owned subsidiary Kite signs partnership deal with Shoreline Biosciences to develop novel cell therapies for cancer.

Blueprint Medicines (BPMC) Gets FDA Nod for Ayvakyt in SM

The FDA approves Blueprint Medicines' (BPMC) lead drug, Ayvakit, for treating adult patients with advanced systemic mastocytosis.

CRISPR (CRSP) Inks Deal for Gene Therapies in Neurological Diseases

CRISPR Therapeutics (CRSP) signs a strategic collaboration with Capsida Biotherapeutics to develop/commercialize gene editing therapies for neurological diseases.

Vertex's (VRTX) Trikafta Gets FDA Nod for CF in Children

The FDA approves Vertex's (VRTX) triple combination therapy, Trikafta, for treating cystic fibrosis in children aged between six to 11 years.

Arena's (ARNA) Etrasimod Gets FDA's Orphan Drug Tag for EoE

The FDA bestows an Orphan Drug status to Arena's (ARNA) lead pipeline candidate, etrasimod, for the treatment of eosinophilic esophagitis.

Alexion's (ALXN) PNH Drug Ultomiris Gets FDA Nod for Kids

The FDA approves Alexion's (ALXN) Ultomiris for the treatment of PNH in children of one month of age and older as well as adolescents.

bluebird (BLUE) Resumes SCD & TDT Studies as FDA Lifts Hold

The FDA lifts the clinical hold on bluebird's (BLUE) studies on LentiGlobin for sickle cell disease and betibeglogene autotemcel for transfusion-dependent thalassemia. Shares rise.

Kamada (KMDA) Q1 Earnings Top Estimates

Kamada (KMDA) delivered earnings and revenue surprises of 20.00% and -5.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Kamada (KMDA) Misses Q4 Earnings and Revenue Estimates

Kamada (KMDA) delivered earnings and revenue surprises of -42.86% and -4.89%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Kamada (KMDA) Q4 Earnings Expected to Decline

Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should Value Investors Consider Kamada (KMDA) Stock Now?

Let's see if Kamada (KMDA) stock is a good choice for value-oriented investors right now from multiple angles.

Kamada (KMDA) Q3 Earnings and Revenues Beat Estimates

Kamada (KMDA) delivered earnings and revenue surprises of 100.00% and 5.50%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Kamada (KMDA) Q3 Earnings Expected to Decline

Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights: TTOO, KMDA and CERS

The Zacks Analyst Blog Highlights: TTOO, KMDA and CERS

Tirthankar Chakraborty headshot

3 Plasma Stocks to Win Big on FDA's Convalescent EUA

Convalescent plasma stocks moved northward following FDA's emergency plasma authorization for COVID-19 treatment. Here're three of them that should be on your watch list -

Kamada (KMDA) Q2 Earnings and Revenues Lag Estimates

Kamada (KMDA) delivered earnings and revenue surprises of -25.00% and -4.40%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Kamada (KMDA) to Report a Decline in Earnings: What to Look Out for

Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kamada (KMDA) Looks Good: Stock Adds 5.7% in Session

Kamada (KMDA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

How Kamada (KMDA) Stock Stands Out in a Strong Industry

Kamada (KMDA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Kamada (KMDA) Q1 Earnings and Revenues Top Estimates

Kamada (KMDA) delivered earnings and revenue surprises of 62.50% and 8.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Kamada (KMDA) to Report a Decline in Earnings: What to Look Out for

Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LYFT, SIX, VIR, RDHL and KMDA as Zacks Bull and Bear of the Day

LYFT, SIX, VIR, RDHL and KMDA as Zacks Bull and Bear of the Day